%0 Journal Article
%T White Paper on Emerging Facilities for Production of Novel Radionuclides for Use in Nuclear Medicine
%U https://zenodo.org/records/17553316
%X The key objective of PRISMAP is to establish a European infrastructure for researchers and physicians, providing a sustainable source of highly pure non-conventional radionuclides for development in medicine as well as protocols and services for the pharmaceutical industry and the healthcare sector. It is composed of a consortium of European facilities for radionuclide production, including high-flux neutron sources, mass separator facilities, and high-power accelerators, with biomedical research institutes and hospitals dedicated to translating emerging radionuclides into medical diagnosis and treatment. PRISMAP focuses on the development and study of non-conventional radionuclides for translational medical research.

This work is part of WP8 of PRISMAP on “Involvement of Emerging Infrastructures”. The goals of this White Paper are: First, to provide a comprehensive list of the emerging facilities which are part of the PRISMAP consortium. These emerging facilities are at different stages of maturity, some are already operating, some are in the design or construction phases, and finally, some are just on paper. Second, to provide results on production capabilities for some of the innovative radionuclides that are part of the PRISMAP portfolio. During the project, two workshops, the first one at INFN in Legnaro, Italy, in 2022, and the second at SCK CEN in 2025, were held as part of the same work package. In the second workshop, preliminary results on calculations for six innovative radionuclides were presented. The final results are summarized in this white paper.



The six radionuclides with high potential in nuclear medicine are Sc-47, Cu-67, Tb-152, Tb-155, Pt-195m and Ac-225. They were selected from the list in the PRISMAP portfolio (Pt-195m while not yet in the PRISMAP portfolio, but had been requested by PRISMAP users) because their production routes at existing facilities are particularly challenging, and it is of vital interest to consider alternative ways at emerging facilities, considering production at particle accelerators, γ-ray beams, and neutron sources, with the possible use of mass separation. As it is shown in the report, the results are extremely encouraging in terms of production capabilities, and all of the emerging facilities can, in one way or the other, contribute to the development and production of these innovative radionuclides. Some challenges remain, and these are discussed in the individual sections dedicated to the radionuclides and in the conclusions.
%A Zanini, Luca
%D 2025-11-07
%K deliverable